{"id":41107,"date":"2017-10-05T21:31:32","date_gmt":"2017-10-06T04:31:32","guid":{"rendered":"http:\/\/drduru.com\/onetwentytwo\/?p=41107"},"modified":"2017-10-06T10:20:57","modified_gmt":"2017-10-06T17:20:57","slug":"dexcom-danger-and-opportunity","status":"publish","type":"post","link":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/","title":{"rendered":"The Danger in DexCom&#8230;and the Opportunity"},"content":{"rendered":"<p>DexCom (DXCM) is a maker of continuous glucose monitoring (CGM) systems. Last week, the stock of the company cratered after Abbott Laboratories (ABT) received FDA approval of its competing <a href=\"https:\/\/www.freestylelibre.us\/\" rel=\"noopener\" target=\"_blank\">FreeStyle Libre flash CGM<\/a>. It is the first system that allows diabetics to check and monitor glucose levels without sticking themselves.<\/p>\n<p><center><br \/>\n<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/HuUTwWRbxwU\" frameborder=\"0\" allowfullscreen><\/iframe><br \/>\n<\/center><\/p>\n<p>In response to the news, analysts downgraded DXCM in droves. ABT apparently received approval earlier than anticipated and entered the market with very aggressive pricing. In Mad Money on October 4, 2017, Jim Cramer reviewed the situation and ultimately concluded that DXCM is a buy on the discount; he was also bullish before the sell-off. Cramer listed the following pros for DXCM contrasted against ABT&#8217;s competitive threat:<\/p>\n<ul>\n<li>More accurate and reliable.<\/li>\n<li>More features: real-time alarms that can wake a person up and remote monitoring which enables parents to track children.<\/li>\n<li>Partnership with Google to create a cheaper and smaller system.<\/li>\n<li>Medicare reimbursement (on this point, I was not clear whether ABT will never be able to receive the same treatment).<\/li>\n<\/ul>\n<p>Cramer also claimed that the number of diabetics who still do no monitoring constitutes a market big enough for both DXCM and ABT to share. Moreover, DXCM managed to bounce back from Medtronic&#8217;s (MDT) roll-out of its &#8220;artificial pancreas.&#8221;<\/p>\n<p>All these positives may be true, but in situations like these I also believe in respecting the technicals. Right now, DXCM is dangerous given the combination of the recent massive breakdown and a slow deterioration from its last all-time high two years ago. DXCM has also yet to confirm a potential end to the selling. In <a href=\"http:\/\/drduru.com\/onetwentytwo\/2015\/12\/16\/anatomy-of-a-bottom-do-not-argue-with-sellers-celebrate-with-buyers\/\" rel=\"noopener\" target=\"_blank\">my guidelines for picking a bottom to buy<\/a>, I recommend avoiding fights with sellers and waiting until buyers show signs of life before buying. The chart of DXCM shows a clear stalemate at a very key technical level.<\/p>\n<p><center><br \/>\n<figure id=\"attachment_41109\" aria-describedby=\"caption-attachment-41109\" style=\"width: 540px\" class=\"wp-caption alignnone\"><a href=\"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg\" alt=\"Dexcom (DXCM) collapsed last week and is now struggling to cling to a very important technical level established from 2014 to 2016\" width=\"550\" height=\"536\" class=\"size-full wp-image-41109\" \/><\/a><figcaption id=\"caption-attachment-41109\" class=\"wp-caption-text\">Dexcom (DXCM) collapsed last week and is now struggling to cling to a very important technical level established from 2014 to 2016<\/figcaption><\/figure><\/p>\n<p><figure id=\"attachment_41110\" aria-describedby=\"caption-attachment-41110\" style=\"width: 540px\" class=\"wp-caption alignnone\"><a href=\"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM-weekly.jpg\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM-weekly.jpg\" alt=\"The weekly chart of Dexcom (DXCM) reveals the growing risk after the stock peaked in 2015. The breakdown from the wedge pattern is very bearish. If the stock sells off further from current support, the bearishness will rapidly worsen.\" width=\"550\" height=\"535\" class=\"size-full wp-image-41110\" \/><\/a><figcaption id=\"caption-attachment-41110\" class=\"wp-caption-text\">The weekly chart of Dexcom (DXCM) reveals the growing risk after the stock peaked in 2015. The breakdown from the wedge pattern is very bearish. If the stock sells off further from current support, the bearishness will rapidly worsen.<\/figcaption><\/figure><br \/>\n<strong>Source: <a href=\"http:\/\/www.freestockcharts.com\/platform\/v1\" rel=\"noopener\" target=\"_blank\">FreeStockCharts.com<\/a><\/strong><br \/>\n<\/center><\/p>\n<p>Based on these charts, any purchase of DXCM here would have to stop out below $42. Using my guidelines, I want to wait to buy DXCM until after it makes a new post sell-off high AND delivers a day of follow-through buying. DXCM fulfilled the criteria in the first two days after the sell-off, but slid backwards the next day. Now, it is pivoting around that important line of support defined by a peak in early 2014 and the low from 2016. Today&#8217;s close was right on that line. The good news is that the intraday lows are gradually going higher. So for now, the odds are in DXCM&#8217;s favor to trigger a new buying signal: a fresh post sell-off high and a day of follow-through buying. I will post a trade alert if DXCM meets the criteria.<\/p>\n<p><center><br \/>\n<iframe width='550' height='360' scrolling='no' frameborder='0' src='https:\/\/finance.yahoo.com\/video\/cramer-remix-mea-culpa-dexcom-231900660.html?format=embed' allowfullscreen='true' mozallowfullscreen='true' webkitallowfullscreen='true' allowtransparency='true'><\/iframe><br \/>\n<\/center><\/p>\n<p>Be careful out there!<\/p>\n<p>Full disclosure: no position<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DexCom (DXCM) is a maker of continuous glucose monitoring (CGM) systems. Last week, the stock of the company cratered after Abbott Laboratories (ABT) received FDA approval of its competing FreeStyle Libre flash CGM. It is the first system that allows diabetics to check and monitor glucose levels without sticking themselves. In response to the news, &#8230; <a title=\"The Danger in DexCom&#8230;and the Opportunity\" class=\"read-more\" href=\"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[393,483,300,511,62,1210],"tags":[1944,1941,1943,1942,713,1945,1320],"class_list":["post-41107","post","type-post","status-publish","format-standard","hentry","category-analyst-coverage","category-breakdown","category-health-care","category-support","category-technical-analysis","category-trading-model","tag-abt","tag-dexcom","tag-diabetes","tag-dxcm","tag-jim-cramer","tag-mdt","tag-medical-devices"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Danger in DexCom...and the Opportunity - ONE-TWENTY TWO: Trading Financial Markets<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Danger in DexCom...and the Opportunity - ONE-TWENTY TWO: Trading Financial Markets\" \/>\n<meta property=\"og:description\" content=\"DexCom (DXCM) is a maker of continuous glucose monitoring (CGM) systems. Last week, the stock of the company cratered after Abbott Laboratories (ABT) received FDA approval of its competing FreeStyle Libre flash CGM. It is the first system that allows diabetics to check and monitor glucose levels without sticking themselves. In response to the news, ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/\" \/>\n<meta property=\"og:site_name\" content=\"ONE-TWENTY TWO: Trading Financial Markets\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-06T04:31:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-10-06T17:20:57+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg\" \/>\n<meta name=\"author\" content=\"Dr. Duru\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@drduru\" \/>\n<meta name=\"twitter:site\" content=\"@drduru\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Duru\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/\"},\"author\":{\"name\":\"Dr. Duru\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"headline\":\"The Danger in DexCom&#8230;and the Opportunity\",\"datePublished\":\"2017-10-06T04:31:32+00:00\",\"dateModified\":\"2017-10-06T17:20:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/\"},\"wordCount\":530,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"image\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/171005_DXCM.jpg\",\"keywords\":[\"ABT\",\"Dexcom\",\"diabetes\",\"DXCM\",\"Jim Cramer\",\"MDT\",\"medical devices\"],\"articleSection\":[\"Analyst Coverage\",\"Breakdown\",\"Health Care\",\"Support\",\"Technical Analysis\",\"Trading Model\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/\",\"name\":\"The Danger in DexCom...and the Opportunity - ONE-TWENTY TWO: Trading Financial Markets\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/171005_DXCM.jpg\",\"datePublished\":\"2017-10-06T04:31:32+00:00\",\"dateModified\":\"2017-10-06T17:20:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#primaryimage\",\"url\":\"http:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/171005_DXCM.jpg\",\"contentUrl\":\"http:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2017\\\/10\\\/171005_DXCM.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2017\\\/10\\\/05\\\/dexcom-danger-and-opportunity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Danger in DexCom&#8230;and the Opportunity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#website\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/\",\"name\":\"ONE-TWENTY TWO: Trading Financial Markets\",\"description\":\"Exploring the poetry in financial markets for students of money and economy since the year 2000.\",\"publisher\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\",\"name\":\"Dr. Duru\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"contentUrl\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"width\":900,\"height\":100,\"caption\":\"Dr. Duru\"},\"logo\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\"},\"sameAs\":[\"http:\\\/\\\/www.drduru.com\\\/onetwentytwo\",\"https:\\\/\\\/www.instagram.com\\\/drduru_market_breadth\\\/\",\"https:\\\/\\\/x.com\\\/drduru\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Danger in DexCom...and the Opportunity - ONE-TWENTY TWO: Trading Financial Markets","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/","og_locale":"en_US","og_type":"article","og_title":"The Danger in DexCom...and the Opportunity - ONE-TWENTY TWO: Trading Financial Markets","og_description":"DexCom (DXCM) is a maker of continuous glucose monitoring (CGM) systems. Last week, the stock of the company cratered after Abbott Laboratories (ABT) received FDA approval of its competing FreeStyle Libre flash CGM. It is the first system that allows diabetics to check and monitor glucose levels without sticking themselves. In response to the news, ... Read more","og_url":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/","og_site_name":"ONE-TWENTY TWO: Trading Financial Markets","article_published_time":"2017-10-06T04:31:32+00:00","article_modified_time":"2017-10-06T17:20:57+00:00","og_image":[{"url":"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg","type":"","width":"","height":""}],"author":"Dr. Duru","twitter_card":"summary_large_image","twitter_creator":"@drduru","twitter_site":"@drduru","twitter_misc":{"Written by":"Dr. Duru","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#article","isPartOf":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/"},"author":{"name":"Dr. Duru","@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"headline":"The Danger in DexCom&#8230;and the Opportunity","datePublished":"2017-10-06T04:31:32+00:00","dateModified":"2017-10-06T17:20:57+00:00","mainEntityOfPage":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/"},"wordCount":530,"commentCount":0,"publisher":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"image":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#primaryimage"},"thumbnailUrl":"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg","keywords":["ABT","Dexcom","diabetes","DXCM","Jim Cramer","MDT","medical devices"],"articleSection":["Analyst Coverage","Breakdown","Health Care","Support","Technical Analysis","Trading Model"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/","url":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/","name":"The Danger in DexCom...and the Opportunity - ONE-TWENTY TWO: Trading Financial Markets","isPartOf":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#website"},"primaryImageOfPage":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#primaryimage"},"image":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#primaryimage"},"thumbnailUrl":"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg","datePublished":"2017-10-06T04:31:32+00:00","dateModified":"2017-10-06T17:20:57+00:00","breadcrumb":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#primaryimage","url":"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg","contentUrl":"http:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2017\/10\/171005_DXCM.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/drduru.com\/onetwentytwo\/2017\/10\/05\/dexcom-danger-and-opportunity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/drduru.com\/onetwentytwo\/"},{"@type":"ListItem","position":2,"name":"The Danger in DexCom&#8230;and the Opportunity"}]},{"@type":"WebSite","@id":"https:\/\/drduru.com\/onetwentytwo\/#website","url":"https:\/\/drduru.com\/onetwentytwo\/","name":"ONE-TWENTY TWO: Trading Financial Markets","description":"Exploring the poetry in financial markets for students of money and economy since the year 2000.","publisher":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/drduru.com\/onetwentytwo\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0","name":"Dr. Duru","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","url":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","contentUrl":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","width":900,"height":100,"caption":"Dr. Duru"},"logo":{"@id":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg"},"sameAs":["http:\/\/www.drduru.com\/onetwentytwo","https:\/\/www.instagram.com\/drduru_market_breadth\/","https:\/\/x.com\/drduru"]}]}},"_links":{"self":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/41107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/comments?post=41107"}],"version-history":[{"count":7,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/41107\/revisions"}],"predecessor-version":[{"id":41136,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/41107\/revisions\/41136"}],"wp:attachment":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/media?parent=41107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/categories?post=41107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/tags?post=41107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}